Investigation of the effects of a new transdermal formulation of systemic diclofenac on the upper gastrointestinal mucosa in patients with low back pain: A comparative study with oral diclofenac Authors: Hiroyuki Fukase, Seiji Futagami, Takatsugu Yamamoto, Tatsuhiro Masaoka, Takaaki Terahara, Koji Okawa, Yusuke Tanaka, Tsuyoshi Mita Published: 2024 ABSTRACT AbstractBackground and AimNon‐steroidal anti‐inflammatory drugs (NSAIDs) are associated with gastrointestinal mucosal damage attributed to a topical effect of NSAIDs on the gastrointestinal mucosa after oral administration and cyclooxygenase‐1 inhibition. Diclofenac sodium systemic patch (DSSP), a transdermal patch from which diclofenac sodium is absorbed through the skin to exert its effects through the circulating blood, is considered to reduce the occurrence of gastrointestinal mucosal damage compared with oral diclofenac. This study aimed to compare the effect of DSSP on the upper gastrointestinal mucosa with that of an orally administered diclofenac sodium tablet (DST).MethodsThis randomized, evaluator‐blinded study included Japanese patients with low back pain (LBP). The patients were administered with either DSSP (150 mg/day) or DST (75 mg/day) for 2 weeks. The primary endpoint was the incidence of gastroduodenal ulcers and/or erosions on upper gastrointestinal endoscopy after the study treatment.ResultsThirty patients each were randomly assigned to the DSSP and DST groups. The incidence of gastroduodenal ulcers and/or erosions was 26.7% and 86.2% in the DSSP and DST groups, respectively. The difference in the incidence was −59.5% (95% confidence interval: −77.0 to −34.6). No adverse events (AEs) were observed in the DSSP group, and 20.0% (6/30 patients) reported mild AEs in the DST group (excluding ulcers and erosions).ConclusionDSSP is associated with a lower risk of gastrointestinal mucosal damage than DST, which has the same active ingredient but uses a different route of administration, in patients with LBP. Introduction Non‐steroidal anti‐inflammatory drugs (NSAIDs) are some of the most frequently prescribed medications worldwide and have anti‐inflammatory, antipyretic, and analgesic effects. 1 Among NSAIDs, diclofenac has particularly strong analgesic and anti‐inflammatory effects and is known to have a more potent inhibitory activity on cyclooxygenase (COX)‐2 than COX‐1. 2 To date, various diclofenac formulations (e.g. oral preparations, ointments/lotions, suppositories, and patches) have been developed and used in clinical practice in many countries. 3 , 4 However, one of the major clinical risks of oral diclofenac is gastrointestinal mucosal damage, which is considered to be caused by a topical effect of diclofenac on the gastrointestinal mucosa after oral administration and COX‐1 inhibition after it enters the blood circulation. 5 , 6 , 7 In Japan, a patch containing 15 mg of diclofenac sodium (DS) per 70 cm2 (7 × 10 cm) has been widely used for the treatment of topical pain. 8 Recently, in Japan, a new DS systemic transdermal patch (DS systemic patch [DSSP]) (ZICTHORU Tapes 75 mg, Hisamitsu Pharmaceutical Co., Inc., Saga, Japan) has been developed mainly for the treatment of cancer pain and low back pain (LBP). The efficacy of DSSP has been verified in a phase III confirmatory study in Japanese patients with LBP. 9 In Japan, DSSP is currently approved for LBP at a dose of 75 mg/day (one patch) or 150 mg/day (two patches) and is widely used in medical practice in Japan. DSSP is a transdermal patch from which DS is absorbed through the skin to exert its systemic effects through the circulating blood like oral preparations. It contains a fivefold higher amount of DS (75 mg) than the same size of the conventional topical diclofenac patch. DSSP is also a patch with improved properties that can increase the transdermal absorption of DS. As systemic transdermal patches can stably maintain a lower plasma drug concentration than other routes of administration, 10 , 11 DSSP may reduce the occurrence of gastrointestinal mucosal damage compared with oral diclofenac. In fact, we compared the influence of DSSP (two patches, 150 mg/day) on the upper gastrointestinal mucosa in healthy subjects with that of loxoprofen sodium tablet (LST) (180 mg/day), which is a widely used NSAID in Japan, and found that the incidence of gastroduodenal ulcers was lower in the DSSP group than in the LST group. 12 This result suggests that DSSP is effective in reducing gastrointestinal mucosal damage, but the limitation of this previous study is that the active ingredients are different. Therefore, we compared the effect of DSSP on the upper gastrointestinal mucosa with that of DS tablets (DSTs) containing the same active ingredient as DSSP. Methods Ethical considerations This study complied with the principles of the Declaration of Helsinki. Before the start of the study, the study protocol and informed consent form were reviewed and approved by the Certified Review Board of the Hattori Clinic, Japan. Written informed consent was obtained from all patients before their participation in the study. This study was registered with the Japan Registry of Clinical Trials (trial registration number: jRCTs031230350). Study design and participants This single‐center, randomized, evaluator‐blinded, active‐controlled, parallel‐group exploratory study was conducted at ICR Clinical Research Hospital Tokyo from October 2023 to November 2023. This study included Japanese patients aged ≥ 40 and < 75 years who were clinically diagnosed with LBP and required treatment with systemic NSAIDs. However, patients with LBP associated with visceral disease, fractures, trauma, infection, rheumatoid arthritis, or tumors were excluded. The main exclusion criteria were as follows: patients with (i) gastrointestinal symptoms; (ii) concurrent or past history of peptic ulcer; (iii) history of gastrointestinal disease within 4 weeks before the start of the observation period; (iv) usage of drugs that affect the upper gastrointestinal mucosa, such as antiulcer drugs, within 4 weeks before the start of the observation period; (v) findings of ulcers, erosions, ≥ 11 petechiae, or active hemorrhage in the esophagus, stomach, pylorus, and/or duodenum on upper gastrointestinal endoscopy (UGE) on the first day of the treatment period; or (vi) positive results for Helicobacter pylori tests (determined by blood antibody concentration measurement using a latex method and a result of ≥ 10 U/mL considered as positive). Procedure This study consisted of a 3‐ to 14‐day observation period and a 2‐week treatment period. No treatments were administered during the observation period. The investigator confirmed the eligibility of patients on the first day of the observation period and the first day of the treatment period. Eligible patients were enrolled in the study and randomized to either the DSSP group or the DST group in a 1:1 ratio by permuted block randomization using an electronic data capture system. Patients in the DSSP group were administered with two patches of DSSP (150 mg) once daily that were replaced every day (after approximately 24 h). In principle, the patches were removed before taking a bath at night, and new patches were applied after the bath. The patches were replaced at the same time of day as far as possible. Patches were applied to the chest, abdomen, upper arm, upper back, lower back, or thigh at a different site from the previous day. Patients in the DST group received one tablet of DST 25 mg three times daily after meals (75 mg/day, the dose approved in Japan). During the study period, the concomitant use of other NSAIDs, drugs that affect the upper gastrointestinal mucosa, such as antiulcer drugs, and triamterene were prohibited. Alcohol or tobacco use was not restricted during the study period, but patients were instructed to maintain a regular lifestyle and not to increase or decrease the frequency and amount of alcohol or tobacco use compared with before participation. Vital signs and subjective and objective symptoms were evaluated on the first day of the observation period, the first day of the treatment period, and at the end of the treatment period (or discontinuation). Laboratory tests were performed on the first day of the observation period and at the end of the treatment period (or at discontinuation). Patients were instructed to record their daily use of the study drug during the treatment period. The investigator or study collaborator confirmed the records of the study drug use. Upper gastrointestinal tract endoscopy was performed on the first day of the treatment period and at the end of the treatment period (or at discontinuation). An independent endoscopic monitoring committee, whose members did not perform the endoscopy, reviewed the endoscopic images of each patient obtained at the end of the treatment period to determine the presence or absence of ulcers and erosions under blinded conditions (not knowing the treatment group of patients). An ulcer was defined as a break in the mucosa that was at least 3 mm in diameter with a distinct depth. An erosion was defined as a definite mucosal break at a superficial depth. The committee members remained blinded to the assigned treatment until the results of all patients were obtained. Endpoints The primary endpoint was the incidence of gastroduodenal ulcers and/or erosions on UGE after the study treatment. The secondary endpoint was the separate incidences of gastric and duodenal ulcers and/or erosions. The incidences of gastroduodenal, gastric, and duodenal ulcers and the numbers of those ulcers and erosions were also evaluated. Other safety endpoints were adverse events (AEs), vital signs (temperature, blood pressure, and pulse rate), and laboratory parameters. Statistical analysis In our previous study comparing the effects of DSSP and LST on the upper gastrointestinal mucosa, the incidence of ulcers and of ulcers and/or erosions in the DSSP group was 3.7% and 29.6%, respectively. 12 Other studies have also indicated that when DST was administered to healthy adults for 2 weeks, the incidence of ulcers was 10.0%. 13 Based on these results, the number of patients necessary to confirm an ulcer in at least one patient was set as 30 per group for a total of 60. The endoscopic analysis set included all enrolled patients who received the study drug at least once and underwent UGE on the first day of the treatment period and at the end of the treatment period (or at discontinuation). The primary analysis set included a group of patients in the endoscopic analysis set who used the study drug in compliance with the protocol. The safety analysis set included all the enrolled patients who received the study drug at least once. A 95% confidence interval (CI) based on the Wilson method was calculated for the incidence of gastroduodenal, gastric, or duodenal ulcers and/or erosions. In addition, the between‐group difference in incidence and its 95% CI, based on an unconditional exact test, were calculated. The same analysis was performed to determine the incidence of ulcers. For post hoc analysis, a P‐value based on an unconditional exact test was calculated for the incidence of gastroduodenal ulcers and of gastroduodenal ulcers and/or erosions. To count ulcers and erosions, histograms were prepared for each site and descriptive statistics were applied. In post hoc analysis, the P‐value based on Welch's test was calculated for the number of gastroduodenal ulcers and gastroduodenal erosions. A two‐sided significance level of 5% and a confidence coefficient of 95% were used. Missing data were treated as missing data without imputation from other data and were not included in the tabulation and calculation of descriptive statistics. Analysis datasets were created, and statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). The AEs were coded using the Medical Dictionary for Regulatory Activities/J version 26.1. Results Patients Figure 1 shows the flow of the patients through the study. Fifty‐nine patients (30 patients in the DSSP group and 29 patients in the DST group) were included in the endoscopic analysis set, while all 60 patients were included in the safety analysis set. Two patients who used prohibited concomitant drugs (one each in the DSSP and DST groups) were included in the endoscopic analysis set because the use of these drugs was considered not to affect the gastrointestinal mucosa, based on the timing and duration of use, dosage form, and so forth. Flow of patients through the study. DSSP, diclofenac sodium systemic patch; DST, diclofenac sodium tablet. There were no notable differences in the patient demographics between the treatment groups (Table 1). Table 1Baseline demographics (endoscopic analysis set) Total N = 59 DSSP group N = 30 DST group N = 29 Sex, n (%)Male28 (47.5)15 (50.0)13 (44.8)Female31 (52.5)15 (50.0)16 (55.2)Age (years)Mean (SD)50.9 (7.5)50.6 (7.2)51.3 (7.9)Range (min, max)40, 6740, 6640, 67Body weight (kg)Mean (SD)62.35 (11.23)63.09 (10.33)61.58 (12.24)Range (min, max)42.7, 97.142.7, 85.446.9, 97.1Height (cm)Mean (SD)165.41 (8.05)165.74 (7.06)165.07 (9.07)Range (min, max)150.8, 186.4150.8, 178.4153.6, 186.4BMI (kg/m2)Mean (SD)22.62 (2.46)22.84 (2.58)22.40 (2.35)Range (min, max)18.6, 29.518.6, 29.519.0, 28.3BMI, body mass index; DSSP, diclofenac sodium systemic patch; DST, diclofenac sodium tablet; SD, standard deviation. Baseline demographics (endoscopic analysis set) Total N = 59 DSSP group N = 30 DST group N = 29 BMI, body mass index; DSSP, diclofenac sodium systemic patch; DST, diclofenac sodium tablet; SD, standard deviation. Primary endpoint The incidence of gastroduodenal ulcers and/or erosions was the primary endpoint and determined as 26.7% and 86.2% in the DSSP and DST groups, respectively. The difference in the incidence (DSSP group − DST group) was −59.5% (95% CI: −77.0 to −34.6), showing a decrease in incidence in the DSSP group compared with that in the DST group (P < 0.0001, post hoc analysis) (Table 2). Table 2Incidences of ulcers and/or erosions (endoscopic analysis set) DSSP group N = 30 DST group N = 29 Difference (DSSP − DST) [95% CI‡] P‐value ‡ , § Incidences of ulcers and/or erosionsGastroduodenalNumber of patients with events825Incidence (%) [95% CI † ]26.7 [14.2 to 44.4]86.2 [69.4 to 94.5]−59.5 [−77.0 to −34.6]< 0.0001GastricNumber of patients with events724Incidence (%) [95% CI † ]23.3 [11.8 to 40.9]82.8 [65.5 to 92.4]−59.4 [−77.0 to −34.5]DuodenalNumber of patients with events37Incidence (%) [95% CI † ]10.0 [3.5 to 25.6]24.1 [12.2 to 42.1]−14.1 [−35.2 to 6.0]Incidences of ulcersGastroduodenalNumber of patients with events111Incidence (%) [95% CI † ]3.3 [0.6 to 16.7]37.9 [22.7 to 56.0]−34.6 [−54.3 to −15.0]0.0009GastricNumber of patients with events011Incidence (%) [95% CI † ]0.0 [0.0 to 11.4]37.9 [22.7 to 56.0]−37.9 [−56.9 to −22.0]DuodenalNumber of patients with events11Incidence (%) [95% CI † ]3.3 [0.6 to 16.7]3.4 [0.6 to 17.2]−0.1 [−15.4 to 14.2] † Wilson score confidence interval. ‡ Unconditional exact test with a two‐sided significance level of 5%. § Post hoc analysis.CI, confidence interval; DSSP, diclofenac sodium systemic patch; DST, diclofenac sodium tablet. Incidences of ulcers and/or erosions (endoscopic analysis set) DSSP group N = 30 DST group N = 29 Wilson score confidence interval. Unconditional exact test with a two‐sided significance level of 5%. Post hoc analysis. CI, confidence interval; DSSP, diclofenac sodium systemic patch; DST, diclofenac sodium tablet. Secondary endpoints Incidences of gastric and of duodenal ulcers and/or erosions The incidence of gastric ulcers and/or erosions was lower in the DSSP group than in the DST group. The findings also suggest that the incidence of duodenal ulcers and/or erosions was lower in the DSSP group than in the DST group (Table 2). Incidence of ulcers The between‐group difference in the incidence of gastric ulcers (DSSP group − DST group) was −37.9% (95% CI: −56.9 to −22.0) and that of duodenal ulcers was −0.1% (95% CI: −15.4 to 14.2). The incidence of gastric ulcers was lower in the DSSP group than in the DST group (Table 2). Number of ulcers and erosions The distribution of the number of ulcers (a) and erosions (b) per site in both groups is shown in Figure 2, and their mean (standard deviation) values are shown in Table 3. Number of gastroduodenal, gastric, or duodenal ulcers (a) and erosions (b) at the end of the treatment period (endoscopic analysis set). , diclofenac sodium systemic patch (DSSP); , diclofenac sodium tablet (DST). Table 3Number of ulcers and erosions (endoscopic analysis set) DSSP group N = 30 DST group N = 29 P‐value † , ‡ Number of ulcersGastroduodenalMean (SD)0.03 (0.18)1.00 (1.67)0.0043Median0.000.00Range (min, max)0, 10, 5GastricMean (SD)0.00 (0.00)0.97 (1.66)Median0.000.00Range (min, max)0, 00, 5DuodenalMean (SD)0.03 (0.18)0.03 (0.19)Median0.000.00Range (min, max)0, 10, 1Number of erosionsGastroduodenalMean (SD)0.50 (0.97)7.17 (7.55)< 0.0001Median0.004.00Range (min, max)0, 30, 29GastricMean (SD)0.43 (0.94)6.62 (7.50)Median0.003.00Range (min, max)0, 30, 29DuodenalMean (SD)0.07 (0.25)0.55 (1.30)Median0.000.00Range (min, max)0, 10, 6 † Welch's test with a two‐sided significance level of 5%. ‡ Post hoc analysis.DSSP, diclofenac sodium systemic patch; DST, diclofenac sodium tablet; SD, standard deviation. Number of ulcers and erosions (endoscopic analysis set) DSSP group N = 30 DST group N = 29 Welch's test with a two‐sided significance level of 5%. Post hoc analysis. DSSP, diclofenac sodium systemic patch; DST, diclofenac sodium tablet; SD, standard deviation. Other safety endpoints A summary of AEs is presented in Table 4. Abdominal pain upper occurred in one patient in the DST group as a specific AE of clinical interest with diclofenac. No serious AEs or AEs leading to discontinuation of the study drug were reported. No clinically relevant changes in vital signs (temperature, blood pressure, and pulse rate) or laboratory parameters were observed after the start of the treatment period. Table 4Summary of adverse events (safety analysis set)All causality, n (%)Causal relationship to study drug cannot be ruled out (adverse reaction), n (%) DSSP group N = 30 DST group N = 30 DSSP group N = 30 DST group N = 30 AEs overall0 (0.0)6 (20.0)0 (0.0)6 (20.0)AE (MedDRA/J PT) † Abdominal discomfort0 (0.0)2 (6.7)0 (0.0)2 (6.7)Abdominal pain upper0 (0.0)1 (3.3)0 (0.0)1 (3.3)Constipation0 (0.0)2 (6.7)0 (0.0)2 (6.7)Stomatitis0 (0.0)2 (6.7)0 (0.0)2 (6.7) † MedDRA/J version 26.1.AE, adverse event; DSSP, diclofenac sodium systemic patch; DST, diclofenac sodium tablet; MedDRA/J, Medical Dictionary for Regulatory Activities/J; PT, preferred term. Summary of adverse events (safety analysis set) DSSP group N = 30 DST group N = 30 DSSP group N = 30 DST group N = 30 MedDRA/J version 26.1. AE, adverse event; DSSP, diclofenac sodium systemic patch; DST, diclofenac sodium tablet; MedDRA/J, Medical Dictionary for Regulatory Activities/J; PT, preferred term. Discussion We conducted this study to compare the effects of DSSP with that of orally administered DST on the upper gastrointestinal mucosa. Our results indicate that the incidence of gastroduodenal ulcers and/or erosions was lower in the DSSP group than in the DST group. These results are similar to the incidence of gastroduodenal ulcers and/or erosions observed in a previous comparison between DSSP and LST (DSSP group: 29.6% [8/27 subjects]; LST group: 60.0% [18/30 subjects]) we had performed in a similarly designed study. 12 None of the patients in the DSSP group and six patients in the DST group complained of subjective gastrointestinal symptoms, which was not inconsistent with the results of the incidence of gastroduodenal ulcers and/or erosions. As per a study to evaluate the protective effects of proton pump inhibitors (PPIs) on gastrointestinal mucosa by comparing the “DST + PPI” group with the “DST + placebo” group, 14 the incidence of gastroduodenal ulcers after a 3‐week treatment was 5.9% (1/17 patients) in the “DST + PPI” group and 21.1% (4/19 patients) in the “DST + placebo” group. Considering these results, the effect of DSSP on the gastrointestinal mucosa in this study may be as small as that of the concomitant use of DST and PPI, although there are differences in the number of patients and study conditions. One reason for the smaller influence of DSSP on the upper gastrointestinal mucosa than that of DST may be that DS, the active ingredient, is absorbed from the skin and not from the upper gastrointestinal tract. It is known that the pathology of NSAID‐induced upper gastrointestinal mucosal damage is caused, in part, by a topical effect on the gastrointestinal mucosa. 5 However, unlike oral medications, DSSP does not have a topical effect on the local gastrointestinal mucosa during DS absorption, which may be one of the reasons for the low influence of DSSP on the gastrointestinal mucosa. In contrast, the incidence of gastric ulcers induced by rectal administration of suppositories, which is absorbed from the middle and lower rectal veins, not from the upper gastrointestinal tract as with patches, was shown to be comparable with that of oral medications. 15 This is probably because absorption of suppositories occurs from the middle and lower rectal veins to the inferior vena cava via the internal iliac vein, resulting in a faster rate of absorption and higher drug concentrations in the blood than oral medications. 16 Another reason is that DSSP stably maintains a lower drug concentration in the blood than DST. Diclofenac has been shown to be highly selective for COX‐2 compared with other NSAIDs such as indomethacin and ibuprofen. However, it is speculated that gastrointestinal mucosal damage associated with the intake of existing systemic diclofenac formulations occurs when a certain dose of diclofenac, considered appropriate to relieve pain, results in the plasma drug concentration greatly exceeding the level required for inhibition of COX‐2, thereby inhibiting not only COX‐2 but also COX‐1. 17 The steady‐state C max after application of two patches of DSSP (150 mg of DS) is estimated to be 196.12 ng/mL. 18 Although the steady‐state C max after repeated administration of DST (25 mg of DS) to Japanese patients has not been reported, the C max after a single administration of DST (25 mg of DS) is 415 ng/mL with a half‐life of 1.2 h; the steady‐state C max after repeated administration of DST is expected to be comparable with the C max after a single administration of DST (415 ng/mL). 18 Therefore, the C max after repeated application of two patches of DSSP is estimated to be approximately half that attained after repeated administration of DST, three times daily. Thus, the effect of DSSP on the upper gastrointestinal mucosa is lesser than that of DST because the plasma drug concentration is lower than that achieved with DST, and the extent of COX‐1 inhibition is relatively reduced. This study has some limitations. First, the duration of treatment in this study was only 2 weeks, which is shorter than the duration of treatment with NSAIDs used for LBP and so forth in clinical settings. It is known that the risk for an influence of NSAIDs on the upper gastrointestinal mucosa is greater in patients using NSAIDs for ≤ 3 months than ≥ 3 months. 19 , 20 Therefore, due to the short treatment period of 2 weeks in this study, the incidence of gastroduodenal ulcers and/or erosions in the DST group may have been higher than that expected in clinical settings. In addition, only the number of lesions was counted in this study, and the results may differ if size, area, and severity of the lesions are included in the evaluation. Second, the patient population in this study was different from that treated in clinical settings. Among the enrolled patients, the percentage of patients aged ≥ 65 years was 3.4%, and the mean age was 50.9 years. Therefore, the population in this study may be biased toward a relatively younger patient population than that likely to require treatment with NSAIDs in the clinical setting. Furthermore, because the exclusion criteria excluded patients with findings of ulcers or erosions and so forth in the stomach or duodenum on UGE on the first day of the treatment period, the population in this study may be biased toward more patients without any injury of the upper gastrointestinal tract than those found in the clinical setting. In addition, it has been reported that the H. pylori infection rate at the mean age of the patients enrolled in this study (50.9 years) is 32.5% in Japan. 21 As H. pylori‐positive patients were excluded from this study, the incidence of ulcers and/or erosions may differ from that observed in clinical settings. Third, the efficacy of DSSP and DST was not evaluated because this study was conducted at the clinically effective doses that have been validated 9 , 22 and approved in Japan. Further studies are needed to compare the correlation with efficacy. In conclusion, DSSP is associated with a lower incidence of gastroduodenal ulcers and/or erosions in patients with LBP than DST, which contains the same active ingredient but has a different route of administration. These results suggest that DSSP has a lower risk of gastrointestinal mucosal damage, a problem associated with NSAID administration, than DST.